泽璟制药(688266.SH)：ZG006和ZG005在2025年欧洲肿瘤内科学会(ESMO)年会发布临床数据

Core Viewpoint - The company Zai Lab (688266.SH) is set to present clinical research data and updates on its self-developed drugs Alveltamig (ZG006) and Nilvanstomig (ZG005) at the European Society for Medical Oncology (ESMO) annual meeting scheduled for October 17-21, 2025 [1] Group 1: Drug Development Progress - ZG006 has demonstrated significant and durable anti-tumor efficacy in patients with advanced small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) who have failed existing standard treatments, along with good tolerability and safety [1] - ZG005, when combined with chemotherapy, has shown good safety and tolerability in patients with advanced neuroendocrine cancer, indicating promising efficacy that supports further clinical research [1]